Jean Addington1, Donald Addington1, Sabina Abidi2, Thomas Raedler1, Gary Remington3,4. 1. 1 Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta. 2. 2 Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia. 3. 3 Department of Psychiatry and Psychological Clinical Science, University of Toronto, Toronto, Ontario. 4. 4 Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ontario.
Abstract
OBJECTIVE: Young people who are at clinical high risk (CHR) of developing psychosis are often help seeking and have significant distress and dysfunction. There are limited guidelines for the assessment and treatment for this population. The aim of this guideline was to develop treatment recommendations for this at-risk group. METHOD: A systematic search was conducted for published guidelines for CHR. All current guidelines for schizophrenia were reviewed for treatment guidelines on individuals at CHR. The recommendations adopted were primarily drawn from the European Psychiatric Association (EPA) guidance on the early intervention in clinical high-risk states of psychoses and the 2014 National Institute for Health and Care Excellence (NICE) guidelines on the treatment and management of those at CHR for psychosis. RESULTS: After the guideline development process described, 9 recommendations were developed based on the quality of evidence, appropriateness for the Canadian health care system, and clinical expert consensus. CONCLUSIONS: Assessment by an expert in the field was the first recommendation. It was recommended that treatment follow a staged approach with psychological treatments being the first-line treatment and pharmacotherapy reserved for adults, those who did not respond to psychological interventions, and those who had more severe symptoms.
OBJECTIVE: Young people who are at clinical high risk (CHR) of developing psychosis are often help seeking and have significant distress and dysfunction. There are limited guidelines for the assessment and treatment for this population. The aim of this guideline was to develop treatment recommendations for this at-risk group. METHOD: A systematic search was conducted for published guidelines for CHR. All current guidelines for schizophrenia were reviewed for treatment guidelines on individuals at CHR. The recommendations adopted were primarily drawn from the European Psychiatric Association (EPA) guidance on the early intervention in clinical high-risk states of psychoses and the 2014 National Institute for Health and Care Excellence (NICE) guidelines on the treatment and management of those at CHR for psychosis. RESULTS: After the guideline development process described, 9 recommendations were developed based on the quality of evidence, appropriateness for the Canadian health care system, and clinical expert consensus. CONCLUSIONS: Assessment by an expert in the field was the first recommendation. It was recommended that treatment follow a staged approach with psychological treatments being the first-line treatment and pharmacotherapy reserved for adults, those who did not respond to psychological interventions, and those who had more severe symptoms.
Entities:
Keywords:
clinical high risk; guidelines; schizophrenia; treatment
Authors: Paolo Fusar-Poli; Giacomo Deste; Renata Smieskova; Stefano Barlati; Alison R Yung; Oliver Howes; Rolf-Dieter Stieglitz; Antonio Vita; Philip McGuire; Stefan Borgwardt Journal: Arch Gen Psychiatry Date: 2012-06
Authors: Melissa C Brouwers; Michelle E Kho; George P Browman; Jako S Burgers; Francoise Cluzeau; Gene Feder; Béatrice Fervers; Ian D Graham; Jeremy Grimshaw; Steven E Hanna; Peter Littlejohns; Julie Makarski; Louise Zitzelsberger Journal: CMAJ Date: 2010-07-05 Impact factor: 8.262
Authors: Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung Journal: JAMA Psychiatry Date: 2013-01 Impact factor: 21.596
Authors: Tyrone D Cannon; Changhong Yu; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Robert Heinssen; Clark D Jeffries; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Michael W Kattan Journal: Am J Psychiatry Date: 2016-07-01 Impact factor: 18.112
Authors: Elizabeth C Thompson; Anthony Spirito; Jiayin Sperry Saarinen; Jennifer C Wolff Journal: Early Interv Psychiatry Date: 2020-09-21 Impact factor: 2.721
Authors: Emma Soneson; Debra Russo; Jan Stochl; Margaret Heslin; Julieta Galante; Clare Knight; Nick Grey; Joanne Hodgekins; Paul French; David Fowler; Louise Lafortune; Sarah Byford; Peter B Jones; Jesus Perez Journal: Aust N Z J Psychiatry Date: 2020-05-28 Impact factor: 5.744
Authors: Alison R Yung; Stephen J Wood; Ashok Malla; Barnaby Nelson; Patrick McGorry; Jai Shah Journal: Psychol Med Date: 2019-10-28 Impact factor: 7.723